Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review

References

• Carvalho AF, Firth J, Vieta E, et al. Bipolar disorder. N Engl J Med. 2020;383(1):58–66. doi: 10.1056/NEJMra1906193
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Alda M, Baldessarini RJ, et al. The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management. World Psychiatry. 2022;21(3):364–387. doi: 10.1002/wps.20997
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–1856. doi: 10.1016/S0140-6736(20)31544-0
   PubMed Web of Science ®Google Scholar
• Martínez-Arán A, Vieta E, Colom F, et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 2004 Jun;6(3):224–32.
   PubMed Web of Science ®Google Scholar
• Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. Neuropsychiatr Dis Treat. 2015 Dec 17;11: 3111–3125. doi: 10.2147/NDT.S76700. PMID: 26719696; PMCID: PMC4689290.
   PubMed Web of Science ®Google Scholar
• Solé B, Bonnin CM, Torrent C, et al. Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatr Scand. 2012 Apr;125(4):309–17.
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence (NICE). Bipolar disorder: assessment and management (clinical guideline, CG 185). London: National Institute of Health and Care Excellence (NICE); 2014.
   Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence‐based guidelines for treating bipolar disorder: revised third edition recommendations from The British association for psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. doi: 10.1177/0269881116636545
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Self‐reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry. 2002;159(11):1927–1929. doi: 10.1176/appi.ajp.159.11.1927
   PubMed Web of Science ®Google Scholar
• Jawad I, Watson S, Haddad PM, et al. Medication nonadherence in bipolar disorder: a narrative review. Ther Adv Psychopharmacol. 2018;8(12):349–363. doi: 10.1177/2045125318804364
   PubMed Web of Science ®Google Scholar
• Ayık B, Baş A, Usta Sağlam NG, et al. The relationship between emotional dysregulation, alexithymia and somatization in patients with bipolar disorder. Alpha Psychiatry. 2023;24(1):15–21. doi: 10.5152/alphapsychiatry.2023.22974
   PubMedGoogle Scholar
• Belzeaux R, Boyer L, Mazzola-Pomietto P, et al. French advanced centers of expertise for bipolar disorders collaborators. Adherence to medication is associated with non-planning impulsivity in euthymic bipolar disorder patients. J Affect Disord. 2015;184:60–66. doi: 10.1016/j.jad.2015.05.041
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta‐analysis of randomised long‐term trials. Schizophr Res. 2011;127(1–3):83–92.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. doi: 10.1176/appi.ajp.2011.10081224
   PubMed Web of Science ®Google Scholar
• Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry. 1994;165(6):827–829. doi: 10.1192/bjp.165.6.827
   PubMedGoogle Scholar
• Gigante AD, Lafer B, Yatham LN Long‐acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNSDrugs. 2012;26(5):403–420. doi: 10.2165/11631310-000000000-00000
   Google Scholar
• Samalin L, Nourry A, Charpeaud T, et al. What is the evidence for the use of second‐generation antipsychotic long‐acting injectables as maintenance treatment in bipolar disorder? Nord J Psychiatry. 2014;68(4):227–235. doi: 10.3109/08039488.2013.801078
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and metaanalysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. doi: 10.4088/JCP.13r08440
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8(5):387–404. doi: 10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Bond DJ, Pratoomsri W, Yatham LN Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand Suppl. 2007;116(434):3–16. doi: 10.1111/j.1600-0447.2007.01054.x
   Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long‐acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156–162. doi: 10.1016/j.biopsych.2010.01.015
   PubMed Web of Science ®Google Scholar
• Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22(11):825–835. doi: 10.1016/j.euroneuro.2012.03.004
   PubMed Web of Science ®Google Scholar
• Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827–839. doi: 10.1111/j.1399-5618.2009.00761.x
   PubMed Web of Science ®Google Scholar
• Yatham LN, Fallu A, Binder CE A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl. 2007;116(434):50–56. doi: 10.1111/j.1600-0447.2007.01059.x
   Google Scholar
• Chengappa KN, Turkin SR, Schlicht PJ, et al. A Pilot, 15‐month, randomised effectiveness trial of risperidone long‐acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder. Acta Neuropsychiatr. 2010;22(2):68–80. doi: 10.1111/j.1601-5215.2010.00458.x
   PubMed Web of Science ®Google Scholar
• Prajapati AR, Wilson J, Song F, et al. Second-generation antipsychotic long-acting injections in bipolar disorder: systematic review and meta-analysis. Bipolar Disord. 2018 Dec;20(8):687–696.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once‐monthly in the maintenance treatment of bipolar I disorder: a double‐blind, placebo‐controlled, 52‐week randomized withdrawal study. J Clin Psychiatry. 2017;78(3):324–331. doi: 10.4088/JCP.16m11201
   PubMed Web of Science ®Google Scholar
• Yıldızhan E, Uzun E, Tomruk NB Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder – a naturalistic mirror image study. Nord J Psychiatry 2022;76(1):37–43. doi: 10.1080/08039488.2021.1931714
   PubMed Web of Science ®Google Scholar
• Caliskan AM, Calisir S, Caliskan S, et al. Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: a mirror image retrospective study. Asian J Psychiatr. 2020;54:102457. doi: 10.1016/j.ajp.2020.102457
   PubMed Web of Science ®Google Scholar
• Bartoli F, Bachi B, Calabrese A, et al. Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: a retrospective mirror-image analysis from the Northern Milan area cohort (NOMIAC) study. J Affect Disord. 2022;318:88–93. doi: 10.1016/j.jad.2022.08.096
   PubMed Web of Science ®Google Scholar
• Bartoli F, Cavaleri D, Callovini T, et al. Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: findings from the STAR network depot study. Psychiatry Res. 2022;309:114405. doi: 10.1016/j.psychres.2022.114405
   PubMed Web of Science ®Google Scholar
• Chan HW, Huang CY, Feng WJ, et al. Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: a 1-year retrospective cohort study. J Affect Disord. 2016;205:360–364. doi: 10.1016/j.jad.2016.08.023
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Chuang PY, Wu CS, et al. Bipolar patients treated with long-acting injectable risperidone in Taiwan: a 1-year mirror-image study using a national claims database. J Affect Disord. 2017;218:327–334. doi: 10.1016/j.jad.2017.04.074
   PubMed Web of Science ®Google Scholar
• Bartoli F, Cavaleri D, Nasti C, et al. Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies. Ther Adv Psychopharmacol. 2023 Mar 25;13:20451253231163682. doi: 10.1177/20451253231163682. PMID: 36994116; PMCID: PMC10041584.
   Web of Science ®Google Scholar